LifeMD, Inc. 10-Q

Item 1. Financial Statements LIFEMD, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) September 30, 2025 December 31, 2024 ASSETS Current Assets Cash $ 23,785,771 $ 35,004,924 Accounts receivable 9,244,321 10,854,084 Product deposit 370,518 40,763 Inventory 3,432,382 2,797,358 Other current assets 4,252,613 3,672,231 Total Current Assets 41,085,605 52,369,360 Non-current Assets Equipment, net 2,584,829 1,479,184 Right of use assets, net 5,578,992 6,400,596 Capitalized software, net 15,175,634 13,816,501 Intangible assets, net 1,558,318 2,030,656 Total Non-current Assets 24,897,773 23,726,937 Total Assets $ 65,983,378 $ 76,096,297 LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Current Liabilities Accounts payable $ 19,554,735 $ 16,009,484 Accrued expenses 22,079,805 22,811,763 Current operating lease liabilities 673,482 508,537 Current portion of convertible long-term debt - 8,444,444 Deferred revenue 14,355,531 19,625,940 Total Current Liabilities 56,663,553 67,400,168 Long-term Liabilities Convertible long-term debt, net - 9,885,057 Noncurrent operating lease liabilities 5,851,673 6,265,192 Contingent consideration 100,000 100,000 Total Liabilities 62,615,226 83,650,417 Commitments and contingencies (Note 11) - Stockholders’ Equity (Deficit) Series A Preferred Stock, $ 0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding, liquidation value approximately, $ 35.8 million as of September 30, 2025 and December 31, 2024 140 140 Common Stock, $ 0.01 par value; 100,000,000 shares authorized, 46,686,350 and 42,293,907 shares issued, 46,583,310 and 42,190,867 outstanding as of September 30, 2025 and December 31, 2024, respectively 466,864 422,939 Additional paid-in capital 248,801,209 230,508,339 Accumulated deficit ( 247,790,178 ) ( 239,850,931 ) Treasury stock, 103,040 , at cost, as of September 30, 2025 and December 31, 2024 ( 163,701 ) ( 163,701 ) Total LifeMD, Inc. Stockholders’ Equity (Deficit) 1,314,334 ( 9,083,214 ) Non-controlling interest 2,053,818 1,529,094 Total Stockholders’ Equity (Deficit) 3,368,152 ( 7,554,120 ) Total Liabilities and Stockholders’ Equity (Deficit) $ 65,983,378 $ 76,096,297 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 LIFEMD, INC. CONDENSED Consolidated STATEMENTS OF OPERATIONS (Unaudited) 2025 2024 2025 2024 Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenues Telehealth revenue, net $ 47,279,933 $ 40,154,683 $ 147,186,714 $ 109,687,054 WorkSimpli revenue, net 12,892,537 13,117,611 39,788,325 39,650,009 Total revenues, net 60,172,470 53,272,294 186,975,039 149,337,063 Cost of revenues Cost of telehealth revenue 6,714,235 4,300,877 21,689,400 13,049,315 Cost of WorkSimpli revenue 693,678 712,664 1,793,133 1,589,318 Total cost of revenues 7,407,913 5,013,541 23,482,533 14,638,633 Gross profit 52,764,557 48,258,753 163,492,506 134,698,430 Expenses Selling and marketing expenses 29,474,490 26,611,672 87,793,648 77,164,480 General and administrative expenses 16,589,390 18,115,143 51,210,246 51,160,883 Customer service expenses 2,784,320 2,804,210 9,086,549 7,385,669 Other operating expenses 3,039,135 2,112,169 8,582,655 6,318,791 Development costs 2,846,436 2,611,833 8,265,842 7,101,655 Total expenses 54,733,771 52,255,027 164,938,940 149,131,478 Operating loss ( 1,969,214 ) ( 3,996,274 ) ( 1,446,434 ) ( 14,433,048 ) Interest expense, net ( 262,456 ) ( 558,597 ) ( 1,551,758 ) ( 1,567,743 ) Loss on debt extinguishment ( 1,155,851 ) - ( 1,155,851 ) - Net loss before income taxes ( 3,387,521 ) ( 4,554,871 ) ( 4,154,043 ) ( 16,000,791 ) Income tax expense ( 169,134 ) ( 232,523 ) ( 169,134 ) ( 232,523 ) Net income (loss) ( 3,556,655 ) ( 4,787,394 ) ( 4,323,177 ) ( 16,233,314 ) Net income (loss) attributable to non-controlling interest 249,462 ( 129,472 ) 1,286,382 237,037 Net loss attributable to LifeMD, Inc. ( 3,806,117 ) ( 4,657,922 ) ( 5,609,559 ) ( 16,470,351 ) Preferred stock dividends ( 776,563 ) ( 776,563 ) ( 2,329,688 ) ( 2,329,688 ) Net loss attributable to LifeMD, Inc. common stockholders $ ( 4,582,680 ) $ ( 5,434,485 ) $ ( 7,939,247 ) $ ( 18,800,039 ) Basic loss per share attributable to LifeMD, Inc. common stockholders $ ( 0.10 ) $ ( 0.13 ) $ ( 0.18 ) $ ( 0.46 ) Diluted loss per share attributable to LifeMD, Inc. common stockholders $ ( 0.10 ) $ ( 0.13 ) $ ( 0.18 ) $ ( 0.46 ) Weighted average number of common shares outstanding: Basic 46,162,625 42,020,965 44,575,553 40,857,344 Diluted 46,162,625 42,020,965 44,575,553 40,857,344 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 4 LIFEMD, INC. CONDENSED Consolidated STATEMENTS of CHANGES IN STOCKHOLDERS’ EQUITY (Deficit) (Unaudited) Shares Amount Shares Amount Capital Deficit Stock Total Interest Total LifeMD, Inc. Series A Preferred Stock Common Stock Additional Paid-in Accumulated Treasury Non- controlling Shares Amount Shares Amount Capital Deficit Stock Total Interest Total Balance, January 1, 2024 1,400,000 $ 140 38,358,641 $ 383,585 $ 217,550,583 $ ( 215,335,665 ) $ ( 163,701 ) $ 2,434,942 $ 1,754,107 $ 4,189,049 Stock compensation expense - - 943,375 9,434 2,534,996 - - 2,544,430 - 2,544,430 Stock issued for noncontingent consideration payment - - 95,821 958 641,042 - - 642,000 - 642,000 Exercise of stock options - - 1,250 13 7,800 - - 7,813 - 7,813 Cashless exercise of warrants - - 1,268,476 12,685 ( 12,685 ) - - - - - Cashless exercise of options - - 64,113 641 ( 641 ) - - - - - Series A Preferred Stock Dividend - - - - - ( 776,563 ) - ( 776,563 ) - ( 776,563 ) Distribution to non-controlling interest - - - - - - - - ( 302,817 ) ( 302,817 ) Net (loss) income - - - - - ( 4,135,750 ) - ( 4,135,750 ) 224,788 ( 3,910,962 ) Balance, March 31, 2024 1,400,000 $ 140 40,731,676 $ 407,316 $ 220,721,095 $ ( 220,247,978 ) $ ( 163,701 ) $ 716,872 $ 1,676,078 $ 2,392,950 Stock compensation expense - - 142,250 1,423 4,189,753 - - 4,191,176 - 4,191,176 Exercise of stock options - - 75,000 750 99,250 - - 100,000 - 100,000 Cashless exercise of stock options - - 448,664 4,487 ( 4,487 ) - - - - - Cashless exercise of warrants - - 361,982 3,620 ( 3,620 ) - - - - - Series A Preferred Stock Dividend - - - - - ( 776,562 ) - ( 776,562 ) - ( 776,562 ) Distribution to non-controlling interest - - - - - - - - ( 264,231 ) ( 264,231 ) Net (loss) income - - - - - ( 7,676,679 ) - ( 7,676,679 ) 141,721 ( 7,534,958 ) Balance, June 30, 2024 1,400,000 $ 140 41,759,572 $ 417,596 $ 225,001,991 $ ( 228,701,219 ) $ ( 163,701 ) $ ( 3,445,193 ) $ 1,553,568 $ ( 1,891,625 ) Stock compensation expense - - 150,000 1,500 2,392,735 - - 2,394,235 - 2,394,235 Series A Preferred Stock Dividend - - - - - ( 776,563 ) - ( 776,563 ) - ( 776,563 ) Distribution to non-controlling interest - - - - - - - - ( 36,000 ) ( 36,000 ) Net loss - - - - - ( 4,657,922 ) - ( 4,657,922 ) ( 129,472 ) ( 4,787,394 ) Balance, September 30,2024 1,400,000 $ 140 41,909,572 $ 419,096 $ 227,394,726 $ ( 234,135,704 ) $ ( 163,701 ) $ ( 6,485,443 ) $ 1,388,096 ( 5,097,347 ) 5 LifeMD, Inc. Series A Preferred Stock Common Stock Additional Paid-in Accumulated Treasury Non- controlling Shares Amount Shares Amount Capital Deficit Stock Total Interest Total Balance, January 1, 2025 1,400,000 $ 140 42,293,907 $ 422,939 $ 230,508,339 $ ( 239,850,931 ) $ ( 163,701 ) $ ( 9,083,214 ) $ 1,529,094 $ ( 7,554,120 ) Stock compensation expense - - 1,282,654 12,827 2,535,701 - - 2,548,528 - 2,548,528 Cashless exercise of stock options - - 56,139 561 ( 561 ) - - - - - Series A Preferred Stock Dividend - - - - - ( 776,563 ) - ( 776,563 ) - ( 776,563 ) Distribution to non-controlling interest - - - - - - - - ( 36,000 ) ( 36,000 ) Net income - - - - - ( 183,778 ) - ( 183,778 ) 531,845 348,067 Balance, March 31, 2025 1,400,000 $ 140 43,632,700 $ 436,327 $ 233,043,479 $ ( 240,811,272 ) $ ( 163,701 ) $ ( 7,495,027 ) $ 2,024,939 $ ( 5,470,088 ) Stock compensation expense - - 346,250 3,463 2,091,151 - - 2,094,614 - 2,094,614 Cashless exercise of stock options - - 50,119 501 ( 501 ) - - - - - Cashless exercise of warrants - - 390,115 3,901 ( 3,901 ) - - - - - Stock issued for debt conversion - - 672,042 6,720 993,280 - - 1,000,000 - 1,000,000 Stock issued for asset acquisition - - 50,000 500 302,500 - - 303,000 - 303,000 Series A Preferred Stock Dividend - - - - - ( 776,562 ) - ( 776,562 ) - ( 776,562 ) Distribution to non-controlling interest - - - - - - - - ( 276,119 ) ( 276,119 ) Net (loss) income - - - - - ( 1,619,664 ) - ( 1,619,664 ) 505,075 ( 1,114,589 ) Balance, June 30, 2025 1,400,000 $ 140 45,141,226 $ 451,412 $ 236,426,008 $ ( 243,207,498 ) $ ( 163,701 ) $ ( 6,493,639 ) $ 2,253,895 $ ( 4,239,744 ) Balance 1,400,000 $ 140 45,141,226 $ 451,412 $ 236,426,008 $ ( 243,207,498 ) $ ( 163,701 ) $ ( 6,493,639 ) $ 2,253,895 $ ( 4,239,744 ) Stock compensation expense - - 655,611 6,556 3,191,480 - - 3,198,036 - 3,198,036 Cashless exercise of stock options - - 25,273 253 ( 253 ) - - - - - Exercise of stock options - - 1,250 13 5,937 - - 5,950 - 5,950 Exercise of warrants - - 100,000 1,000 463,950 - - 464,950 - 464,950 Sale of common stock under ATM, net - - 762,990 7,630 8,714,087 - - 8,721,717 - 8,721,717 Series A Preferred Stock Dividend - - - - - ( 776,563 ) - ( 776,563 ) - ( 776,563 ) Distribution to non-controlling interest - - - - - - - - ( 449,539 ) ( 449,539 ) Net (loss) income - - - - - ( 3,806,117 ) - ( 3,806,117 ) 249,462 ( 3,556,655 ) Balance, September 30, 2025 1,400,000 $ 140 46,686,350 $ 466,864 $ 248,801,209 $ ( 247,790,178 ) $ ( 163,701 ) $ 1,314,334 $ 2,053,818 $ 3,368,152 Balance 1,400,000 $ 140 46,686,350 $ 466,864 $ 248,801,209 $ ( 247,790,178 ) $ ( 163,701 ) $ 1,314,334 $ 2,053,818 $ 3,368,152 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 6 LIFEMD, INC. CONDENSED Consolidated STATEMENTS OF CASH FLOWS (Unaudited) 2025 2024 Nine Months Ended September 30, 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ ( 4,323,177 ) $ ( 16,233,314 ) Adjustments to reconcile net loss to net cash provided by operating activities: Amortization of debt discount 234,369 301,331 Amortization of capitalized software 7,087,054 5,884,893 Amortization of intangibles 775,338 737,836 Accretion of consideration payable - 13,644 Loss on debt extinguishment 1,155,851 - Depreciation of fixed assets 609,569 321,698 Noncash operating lease expense 821,604 529,038 Stock compensation expense 7,841,178 9,129,841 Changes in Assets and Liabilities Accounts receivable 1,609,763 ( 5,222,534 ) Product deposit ( 329,755 ) 349,095 Inventory ( 635,024 ) 114,489 Other current assets ( 580,382 ) ( 2,303,495 ) Operating lease liabilities ( 248,574 ) ( 446,682 ) Deferred revenue ( 5,270,408 ) 10,874,430 Accounts payable 3,545,251 4,782,614 Accrued expenses ( 731,959 ) 7,607,005 Net cash provided by operating activities 11,560,698 16,439,889 CASH FLOWS FROM INVESTING ACTIVITIES Cash paid for capitalized software costs (a) ( 8,446,187 ) ( 7,546,346 ) Purchase of equipment ( 1,715,214 ) ( 1,265,447 ) Purchase of intangible assets - ( 3,798 ) Net cash used in investing activities ( 10,161,401 ) ( 8,815,591 ) CASH FLOWS FROM FINANCING ACTIVITIES Repayment of debt instruments ( 18,719,721 ) - Sale of common stock under ATM, net 8,721,717 - Preferred stock dividends ( 2,329,688 ) ( 2,329,688 ) Repayment of notes payable, net of prepayment penalty - ( 327,597 ) Cash proceeds from exercise of warrants 464,950 - Cash proceeds from exercise of options 5,950 107,813 Contingent consideration payments for ResumeBuild acquisition - ( 31,250 ) Distributions to non-controlling interest ( 761,658 ) ( 603,048 ) Net cash used in financing activities ( 12,618,450 ) ( 3,183,770 ) Net (decrease) increase in cash ( 11,219,153 ) 4,440,528 Cash at beginning of period 35,004,924 33,146,725 Cash at end of period $ 23,785,771 $ 37,587,253 Cash paid for interest and taxes Cash paid during the period for interest $ 1,461,032 $ 1,913,049 Cash paid during the period for taxes $ 482,471 $ 198,176 Non-cash investing and financing activities: Cashless exercise of options $ 1,315 $ 5,127 Cashless exercise of warrants $ 3,901 $ 16,305 Stock issued for debt conversion $ 1,000,000 $ - Stock issued for asset acquisition $ 303,000 $ - Stock issued for noncontingent consideration payment $ - $ 642,000 Right of use assets $ - $ 6,684,397 Operating lease liabilities $ - $ 6,684,397 (a) Approximately $ 2.9 million and $ 2.7 million was paid to a related party for capitalized software costs during the nine months ended September 30, 2025 and 2024, respectively. See Note 12—Related Party Transactions. The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 7 LIFEMD, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 – NATURE OF THE ORGANIZATION AND BUSINESS Corporate History LifeMD, Inc. was formed in the State of Delaware on May 24, 1994, under its prior name, Immudyne, Inc. The Company changed its name to Conversion Labs, Inc. on June 22, 2018 and then subsequently, on February 22, 2021, it changed its name to LifeMD, Inc. Effective February 22, 2021, the trading symbol for the Company’s common stock, par value $ 0.01 per share on The Nasdaq Stock Market LLC changed from “CVLB” to “LFMD”. On April 1, 2016, the original operating agreement of Immudyne PR LLC (“Immudyne PR”), a joint venture to market the Company’s skincare products, was amended and restated and the Company increased its ownership and voting interest in Immudyne PR to 78.2 %. Concurrent with the name change of the parent company to Conversion Labs, Inc., Immudyne PR was renamed to Conversion Labs PR LLC (“Conversion Labs PR”). On April 25, 2019, the operating agreement of Conversion Labs PR was amended and restated in its entirety to increase the Company’s ownership and voting interest in Conversion Labs PR to 100 %. On February 22, 2021, concurrent with the name of the parent company to LifeMD, Inc., Conversion Labs PR was renamed to LifeMD PR, LLC. In June 2018, the Company closed the strategic acquisition of 51 % of LegalSimpli Software, LLC, which operates a software as a service application for converting, editing, signing, and sharing PDF documents called PDFSimpli. On July 15, 2021, LegalSimpli Software, LLC, changed its name to WorkSimpli Software LLC, (“WorkSimpli”). As a result of a series of restructuring transactions, the Company’s ownership interest in WorkSimpli is 73.3 %. On November 4, 2025, LifeMD, Inc. sold its majority ownership interest in WorkSimpli to Lion Buyer, LLC. For a description of the transaction, see Note 15—Subsequent Events. Unless otherwise indicated, the terms “LifeMD,” “Company,” “we,” “us,” and “our” refer to LifeMD, Inc. (formerly known as Conversion Labs, Inc.), LifeMD Pharmacy Holdings LLC, an affiliated limited liability company, (“LifeMD Pharmacy”) and our majority-owned subsidiary, WorkSimpli. The affiliated network of medical Professional Corporations and medical Professional Associations administratively led by LifeMD Southern Patient Medical Care, P.C. (“LifeMD PC”) is the Company’s affiliated, variable interest entity in which we hold a controlling financial interest. Unless otherwise specified, all dollar amounts are expressed in United States dollars. Nature of Business The Company is a direct-to-patient telehealth company providing virtual and in-home healthcare. The Company is improving the delivery of the healthcare experience through telehealth with its proprietary technology platform, affiliated and dedicated provider network, broad and expanding treatment capabilities, and the unique ability to nurture patient relationships. Direct-to-patient telehealth technology companies, like the Company, connect consumers to affiliated, licensed, healthcare professionals for care across numerous indications, including virtual medical care, weight loss, sexual health, hormone replacement therapy, hair loss and other conditions. The Company’s telehealth platform helps patients access their licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis. In addition to its telehealth prescription offerings, the Company sells over-the-counter (“OTC”) products. All products are available on a subscription or membership basis, where a patient can subscribe to receive regular shipments of prescribed medications or products. This creates convenience and often discounted pricing opportunities for patients and recurring revenue streams for the Company. With its first brand, ShapiroMD, the Company has built a full line of proprietary OTC products for male and female hair loss including Food and Drug Administration (“FDA”) approved OTC minoxidil and an FDA-cleared medical device and a personalized telehealth platform offering that gives consumers access to virtual medical treatment from their providers and, when appropriate, a full line of oral and topical prescription medications for hair loss. The Company’s men’s brand, RexMD, currently offers access to virtual medical treatment for a variety of men’s health needs, including erectile dysfunction, premature ejaculation and hair loss. In the first quarter of 2022, the Company launched our virtual primary care offering under the LifeMD brand, LifeMD Primary Care. This offering provides patients with access to affiliated high-quality providers for their urgent care and chronic care needs. In April 2023, we launched our GLP-1 Weight Management Program providing primary care, metabolic coaching, lab work, and prescription services (as appropriate) to patients seeking to access a medically supported weight loss solution. In September 2024, we expanded our Weight Management Program with a personalized, non-GLP-1 treatment plan consisting of three oral medications – metformin, bupropion, and topiramate. 8 Liquidity Evaluation As of September 30, 2025, the Company has an accumulated deficit of approximately $ 247.8 million and a working capital deficit of approximately $ 15.6 million. The working capital deficit includes approximately $ 14.4 million of deferred revenue for which the Company expects to recognize into revenue within 12 months. The Company has incurred significant operating losses and to date, has been funding operations primarily through the sales of its products, issuance of common and preferred stock, and through loans and advances. On March 21, 2023, the Company entered into and closed on a loan and security agreement (the “Avenue Credit Agreement”), and a supplement to the Credit Agreement (the “Avenue Supplement”), with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P. (collectively, “Avenue”). The Avenue Credit Agreement provided for a convertible senior secured credit facility of up to an aggregate amount of $ 40 million, comprised of the following: (1) $ 15 million in term loans funded at closing, (2) $ 5 million of additional committed term loans which the Company received on September 26, 2023 under the First Amendment to the Avenue Credit Agreement (the “Avenue First Amendment”) and (3) $ 20 million of additional uncommitted term loans, collectively referred to as the “Avenue Facility”. The Company issued Avenue warrants to purchase $ 1.2 million of the Company’s common stock at an exercise price of $ 1.24 , subject to adjustments, of which $ 660 thousand have been exercised (the “Avenue Warrants”). In addition, Avenue converted $ 2 million of the $ 15 million in term loans funded at closing into shares of the Company’s common stock at a price per share equal to $ 1.49 . Proceeds from the Avenue Facility were used to repay the Company’s outstanding notes payable balances with CRG Financial. On August 5, 2025, the Company paid the remaining $ 14.0 million in outstanding principal payments on the Avenue Facility and the prepayment penalty as noted in the Avenue Credit Agreement. As of September 30, 2025, there are no principal payments remaining on the Avenue Facility. The Company recorded a loss on debt extinguishment of approximately $ 1.2 million within its unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2025. The Company entered into an At Market Issuance Sales Agreement (the “ATM Sales Agreement”) with B. Riley Securities, Inc. and Cantor Fitzgerald & Co. relating to the sale of its common stock. In accordance with the terms of the ATM Sales Agreement, the Company may, but is not obligated to, offer and sell, from time to time, shares of common stock, through or to the Agents, acting as agent or principal. Sales of common stock, if any, will be made by any method permitted that is deemed an “at the market offering” as defined in Rule 415 under the Securities Act. On June 7, 2024, the Company filed a shelf registration statement on Form S-3 under the Securities Act, which was declared effective on July 18, 2024 (the “2024 Shelf”). Under the 2024 Shelf at the time of effectiveness, the Company had the ability to raise up to $ 150.0 million by selling common stock, preferred stock, debt securities, warrants, and units including $ 53.3 million of its common stock under the ATM Sales Agreement. During the three months ended September 30, 2025, the Company sold 762,990 shares of common stock under the ATM Sales Agreement, with approximately $ 270 thousand in fees paid to the sales agent and net proceeds of $ 8.7 million. As of September 30, 2025, the Company had $ 44.6 million available under the ATM Sales Agreement. The Company expects that its existing cash as of September 30, 2025 of $ 23.8 million will be sufficient to fund our planned operating expenses and capital expenditure requirements for at least the next 12 months from the issuance date of these unaudited condensed consolidated financial statements. NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by accounting principles generally accepted in the United States (“U.S. GAAP”) for complete audited financial statements. The accompanying unaudited financial information should be read in conjunction with the audited consolidated financial statements, including the notes thereto, as of and for the year ended December 31, 2024, included in our 2024 Annual Report on Form 10-K filed with the SEC. The information furnished in this report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for the fair statement of our financial position, results of operations and cash flows for each period presented. The results of operations for the three and nine months ended September 30, 2025 are not necessarily indicative of the results for the year ending December 31, 2025 or for any future period. 9 Principles of Consolidation The Company evaluates the need to consolidate affiliates based on standards set forth in Accounting Standards Codification (“ASC”) 810, Consolidation . The unaudited condensed consolidated financial statements include the accounts of the Company, LifeMD Pharmacy, its majority owned subsidiary, WorkSimpli, and LifeMD PC, the Company’s affiliated, variable interest entity in which we hold a controlling financial interest. All intercompany transactions and balances have been eliminated in consolidation. Cash The Company maintains deposits in financial institutions that may, at times, exceed amounts guaranteed by the Federal Deposit Insurance Corporation. These balances could be impacted if one or more of the financial institutions in which we deposit monies fails or is subject to other adverse conditions in the financial or credit markets. We have never experienced any losses related to these balances. Variable Interest Entities In accordance with ASC 810, Consolidation , the Company determines whether any legal entity in which the Company becomes involved is a variable interest entity (a “VIE”) and subject to consolidation. This determination is based on whether an entity has sufficient equity at risk to finance their activities without additional subordinated financial support from other parties or whose equity investors lack any of the characteristics of a controlling financial interest and whether the interest will absorb portions of a VIE’s expected losses or receive portions of its expected residual returns and are contractual, ownership, or pecuniary in nature and that change with changes in the fair value of the entity’s net assets. A reporting entity is the primary beneficiary of a VIE and must consolidate it when that party has a variable interest, or combination of variable interests, that provides it with a controlling financial interest. A party is deemed to have a controlling financial interest if it meets both of the power and losses/benefits criteria. The power criterion is the ability to direct the activities of the VIE that most significantly impact its economic performance. The losses/benefits criterion is the obligation to absorb losses from, or right to receive benefits from, the VIE that could potentially be significant to the VIE. The Company determined that the LifeMD PC entity, the Company’s affiliated network of medical Professional Corporations and medical Professional Associations administratively led by LifeMD Southern Patient Medical Care, P.C., is a VIE and subject to consolidation. LifeMD PC and the Company do not have any stockholders in common. LifeMD PC is owned by licensed physicians, and the Company maintains a managed service agreement with LifeMD PC whereby we provide all non-clinical services to LifeMD PC. The Company determined that it is the primary beneficiary of LifeMD PC and must consolidate, as we have both the power to direct the activities of LifeMD PC that most significantly impact the economic performance of the entity and we have the obligation to absorb the losses. As a result, the Company presents the financial position, results of operations, and cash flows of LifeMD PC as part of the unaudited condensed consolidated financial statements of the Company. There is no non-controlling interest upon consolidation of LifeMD PC. Total net loss for LifeMD PC was approximately $ 3.8 million and $ 4.0 million for the three months ended September 30, 2025 and 2024, respectively, and $ 10.5 million and $ 10.0 million for the nine months ended September 30, 2025 and 2024, respectively. Total assets and liabilities for the LifeMD PC were approximately $ 13 thousand and $ 649 thousand, respectively, as of September 30, 2025 and $ 8 thousand and $ 380 thousand, respectively, as of December 31, 2024. Use of Estimates The Company prepares its unaudited condensed consolidated financial statements in conformity with U.S. GAAP which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers , when control of the promised goods or services is transferred to customers in an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model to recognize revenue from contracts with customers: 1. Identification of the contract with a customer; 2. Identification of the performance obligations in the contract; 3. Determination of the transaction price; 4. Allocation of the transaction price to the performance obligations in the contract; and 5. Recognition of revenue when, or as, the performance obligations are satisfied. 10 Telehealth Subscription Revenue For the Company’s telehealth subscription arrangements, the Company provides both one-time and subscription-based access to its telehealth platform. The Company offers monthly and multi-month subscriptions dependent upon the subscriber’s enrollment selection. The Company has determined that there is one performance obligation that is delivered over time, as the Company allows the subscriber continuous access to the telehealth platform for the time period of the subscription. The telehealth platform access is a stand-ready obligation that is satisfied over the subscription period. The Company also offers bundled arrangements in which a subscriber receives subscription-based access to the Company’s telehealth platform as well as prescribed medication. The Company has determined that there are two performance obligations related to these bundles: (i) one performance obligation for the subscription-based service that is a stand-ready obligation that is satisfied over the subscription period and (ii) one performance obligation for the prescribed medication that is delivered as of a point in time. For contracts with multiple performance obligations, the transaction price is allocated to each performance obligation based on their relative standalone selling prices, determined from the prices at which the Company separately sells these products and services. Revenue related to contracts with multiple performance obligations was approximately $ 2.5 million and $ 8.9 million for the three months ended September 30, 2025 and 2024, respectively, and $ 10.7 million and $ 22.6 million for the nine months ended September 30, 2025 and 2024, respectively. Additionally, to fulfill its promise to customers for contracts that include the sale of prescription products, the Company maintains relationships with certain third-party pharmacies, which are licensed mail order pharmacies providing prescription fulfillment to the Company’s customers. The third-party pharmacies fill prescription orders for customers who have received a prescription from a LifeMD PC provider. The Company may account for prescription product revenue as the principal or agent in the arrangement with its customers depending on the agreement with the related third-party pharmacy. The following factors are evaluated to determine if the Company acts as principal or agent in the arrangement: (i) whether the Company has sole discretion in determining which pharmacy fills a customer’s prescription; (ii) whether the Company obtains control of the product; (iii) whether the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order; (iv) whether the Company is responsible for refunds of the prescription medication after transfer of control to the customer; and (v) whether the Company sets all listed prices for the prescription products. Based on evaluation of these factors, the Company accounts for prescription product revenue as the agent in the arrangement with its largest third-party pharmacy provider. Telehealth Product Revenue For the Company’s product-based arrangements, the Company has determined that there is a single performance obligation, which is the delivery of the product. Revenue is recognized at a point in time when control transfers to the customer, which occurs upon shipment. The Company generally records sales of finished products when the customer places and pays for the order, with products fulfilled and simultaneously shipped either by the Company or a third-party fulfillment provider. When shipment does not occur concurrently with payment, revenue recognition is deferred until the product is shipped. The Company also provides subscription-based arrangements involving recurring shipments of products. Revenue from these recurring product shipments is recognized at the time each shipment obligation is fulfilled. Provisions for discounts, returns, allowances, customer rebates, and similar adjustments are recorded as reductions to gross revenue in the same period in which related sales are recognized. Discounts and rebates are known at the time of sale, while estimates for returns and allowances are based on historical data and applied consistently across the Company’s product portfolio. Customer discounts, returns and rebates on telehealth subscription and product revenues approximated $ 1.2 million and $ 1.0 million, during the three months ended September 30, 2025 and 2024, respectively, and $ 3.6 million and $ 2.8 million, during the nine months ended September 30, 2025 and 2024, respectively. 11 WorkSimpli Revenue The Company, through its majority-owned subsidiary WorkSimpli, offers a subscription-based service providing a suite of software applications to its subscribers, principally on a monthly subscription basis. The software suite allows the subscriber to convert almost any type of document to another electronic form of editable document, providing ease of editing. For these subscription-based contracts with customers, the Company offers an initial 14-day trial period which is billed at $ 1.95 , followed by a monthly subscription, or a multi-month subscription to the Company’s software suite dependent on the subscriber’s enrollment selection. The Company offers monthly and multi-month subscriptions dependent upon the subscriber’s enrollment selection. The Company has determined that there is one performance obligation that is delivered over time, as the Company allows the subscriber continuous access to the WorkSimpli platform for the time period of the subscription. The WorkSimpli platform access is a stand-ready obligation that is satisfied over the subscription period. The Company allows the customer to cancel at any point during the billing cycle, in which case the customer’s subscription will not be renewed for the following month or year depending on the original subscription. The Company offers a discount for the monthly or multi-month subscriptions being purchased, which is deducted at the time of payment at the initiation of the contract term; therefore the contract price is fixed and determinable at the contract initiation. Monthly and multi-month subscriptions for the service are recorded net of the Company’s known discount rates. Customer discounts and allowances on WorkSimpli revenues approximated $ 900 thousand and $ 1.1 million during the three months ended September 30, 2025 and 2024, respectively, and $ 2.9 million and $ 2.5 million during the nine months ended September 30, 2025 and 2024, respectively. Collaboration Revenue On December 11, 2023, the Company entered into a collaboration with Medifast, Inc. through and with certain of its wholly-owned subsidiaries (“Medifast”). Pursuant to certain agreements between the parties, Medifast agreed to pay to the Company the amount of $ 10 million to support the collaboration, funding enhancements to the Company platform, operations and supporting infrastructure, of which $ 5 million was paid at the closing on December 12, 2023, $ 2.5 million was paid during the three months ended March 31, 2024, and the remaining $ 2.5 million was paid during the three months ended June 30, 2024 (the “Medifast Collaboration”). The Company determined the transaction price totaled $ 10 million, which was fully collected as of December 31, 2024. The Company has allocated the total $ 10 million initial transaction price to three distinct performance obligations. As the Company completed its first performance obligation related to this agreement as of December 31, 2023, the $ 5 million payment was fully recognized during the year ended December 31, 2023. The Company recognized approximately $ 2 million related to the second performance obligation during the three months ended March 31, 2024, and approximately $ 3 million related to the second and third performance obligations during the three months ended June 30, 2024. For the three and nine months ended September 30, 2025 and 2024, the Company had the following disaggregated revenue: SCHEDULE OF DISAGGREGATED REVENUE Three Months Ended September 30, Nine Months Ended September 30, 2025 % 2024 % 2025 % 2024 % Telehealth subscription revenue $ 27,300,431 45 % $ 20,929,511 39 % $ 86,452,443 46 % $ 45,224,718 30 % Telehealth product revenue 19,979,502 33 % 19,225,172 36 % 60,734,271 33 % 59,462,336 40 % WorkSimpli revenue 12,892,537 22 % 13,117,611 25 % 39,788,325 21 % 39,650,009 27 % Medifast collaboration revenue - - % - - % - - % 5,000,000 3 % Total revenues, net $ 60,172,470 100 % $ 53,272,294 100 % $ 186,975,039 100 % $ 149,337,063 100 % Deferred Revenues The Company records deferred revenues when cash payments are received or due in advance of its performance. As of September 30, 2025 and December 31, 2024, the Company has accrued contract liabilities, as deferred revenue, of approximately $ 14.4 million and $ 19.6 million, respectively, which represent the following: (1) $ 10.1 million and $ 14.7 million as of September 30, 2025 and December 31, 2024, respectively, related to obligations on telehealth in-process monthly or multi-month contracts with customers, (2) $ 2.1 million and $ 2.4 million as of September 30, 2025 and December 31, 2024, respectively, related to obligations for telehealth products which the customer has not yet obtained control due to non-shipment of the product and (3) $ 2.2 million and $ 2.5 million as of September 30, 2025 and December 31, 2024, respectively, related to obligations on WorkSimpli in-process monthly or multi-month contracts with customers. The amount of revenue recognized during the nine months ended September 30, 2025, that was included in the deferred revenue balance as of December 31, 2024, was $ 17.3 million. The Company expects to recognize all of the deferred revenue related to future performance obligations that are unsatisfied or partially unsatisfied as of September 30, 2025 as revenue by September 30, 2026. The following table summarizes deferred revenue activities for the periods presented: SCHEDULE OF CONTRACT WITH CUSTOMER LIABILITY 2025 2024 2025 2024 Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Beginning of period $ 16,902,735 $ 18,437,744 $ 19,625,940 $ 9,711,305 Additions 56,242,474 54,736,927 178,513,347 152,312,589 Revenue recognized ( 58,789,678 ) ( 52,588,936 ) ( 183,783,756 ) ( 141,438,159 ) End of period $ 14,355,531 $ 20,585,735 $ 14,355,531 $ 20,585,735 12 Leases The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets are included in right-of-use assets on the unaudited condensed consolidated balance sheets. The current and long-term components of operating lease liabilities are included in the current operating lease liabilities and noncurrent operating lease liabilities, respectively, on the unaudited condensed consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. Certain leases may include options to extend or terminate the lease. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded in the balance sheet. Accounts Receivable, net Accounts receivable principally consist of payments due from merchant processors for the settlement of credit card transactions with customers. The merchant accounts receivable balance represents the charges processed by the merchants that have not yet been deposited with the Company. The unsettled merchant receivable amount normally represents processed sale transactions from the final one to three days of the month, with collections being made by the Company within the first week of the following month. Management determines the need, if any, for an allowance for future credits to be granted to customers, by regularly evaluating aggregate customer refund activity, coupled with the consideration and current economic conditions in its evaluation of an allowance for future refunds and chargebacks. As of September 30, 2025 and December 31, 2024, the reserve for sales returns and allowances was approximately $ 739 thousand and $ 894 thousand, respectively. For all periods presented, the sales returns and allowances were recorded in accrued expenses on the unaudited condensed consolidated balance sheets. The Company’s accounts receivable balances are as follows for each of the periods presented: SCHEDULE OF ACCOUNTS RECEIVABLE September 30, December 31, 2025 2024 Beginning of period $ 10,854,084 $ 6,265,762 End of period $ 9,244,321 $ 10,854,084 Inventory As of September 30, 2025 and December 31, 2024, inventory primarily consisted of finished goods, raw materials and packaging related to the Company’s OTC products included in the telehealth product revenue section of the table above. Inventory is maintained at the Company’s third-party warehouse location in Wyoming and at various Amazon fulfillment centers. The Company also maintains inventory at a company owned warehouse in Pennsylvania. Inventory is valued at the lower of cost or net realizable value with cost determined on an average cost basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down inventory to net realizable, if lower. As of September 30, 2025 and December 31, 2024, the Company recorded an inventory reserve of approximately $ 153 thousand and $ 263 thousand, respectively. As of September 30, 2025 and December 31, 2024, the Company’s inventory consisted of the following: SUMMARY OF INVENTORY September 30, December 31, 2025 2024 Finished goods $ 2,654,421 $ 1,554,600 Raw materials and packaging components 931,352 1,506,078 Inventory reserve ( 153,391 ) ( 263,320 ) Total inventory, net $ 3,432,382 $ 2,797,358 Product Deposit Many of our vendors require deposits when a purchase order is placed for goods or fulfillment services. These deposits typically range from 10 % to 33 % of the total purchased amount. Our vendors include a credit memo within their final invoice, recognizing the deposit amount previously paid. As of September 30, 2025 and December 31, 2024, the Company has approximately $ 371 thousand and $ 41 thousand, respectively, of product deposits with multiple vendors for the purchase of raw materials or finished goods. The Company’s history of product deposits with its inventory vendors, creates an implicit purchase commitment equaling the total expected product acceptance cost in excess of the product deposit. As of September 30, 2025, the Company approximates its implicit purchase commitments to be $ 727 thousand, of which the majority are with three vendors that manufacture the Company’s finished goods inventory for its RexMD product line. 13 Capitalized Software Costs The Company capitalizes certain internal payroll costs and third-party costs related to internally developed software and amortizes these costs using the straight-line method over the estimated useful life of the software, generally three years. The Company does not sell internally developed software other than through the use of subscription service. Certain development costs not meeting the criteria for capitalization, in accordance with ASC 350-40 , Internal-Use Software , are expensed as incurred. As of September 30, 2025 and December 31, 2024, the Company capitalized a net amount of $ 15.2 million and $ 13.8 million, respectively, related to internally developed software costs which are amortized over the useful life and included in development costs on our unaudited condensed consolidated statement of operations. Intangible Assets Intangible assets are comprised of: (1) the ResumeBuild brand, (2) a customer relationship asset, (3) the Cleared Technologies, PBC (“Cleared”) trade name, (4) Cleared developed technology, (5) a purchased license, (6) four purchased domain names and (7) the Optimal Human Health MD (“OHHMD”) brand. Intangible assets are amortized over their estimated lives using the straight-line method. Costs incurred to renew or extend the term of recognized intangible assets are capitalized and amortized over the useful life of the asset which typically range from one year to ten years . Impairment of Long-Lived Assets Long-lived assets include equipment and capitalized software. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If such assets are considered to be impaired, an impairment is recognized as the amount by which the carrying amount of the assets exceeds the estimated fair values of the assets. As of September 30, 2025 and December 31, 2024, the Company determined that no events or changes in circumstances existed that would indicate any impairment of its long-lived assets. Income Taxes The Company files corporate federal, state, and local tax returns. WorkSimpli files a tax return in Puerto Rico. The Company records current and deferred taxes in accordance with ASC 740, Accounting for Income Taxes . ASC 740 requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses. Management determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position would be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company’s tax returns for all years since December 31, 2021, remain open to audit by all related taxing authorities. The Company has net operating loss carryforwards for federal income tax reporting purposes that may be applied against current and future taxable income. All remaining net operating loss carryforwards were generated after 2017 and can be carried forward indefinitely. The Company has fully reserved the deferred tax asset resulting from available net operating loss carryforwards. Stock-Based Compensation The Company follows the provisions of ASC 718, Share-Based Payment . Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting or service period. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company’s common shares using daily price observations over an observation period that approximates the expected life of the options. The risk-free interest rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the Company has elected to account for forfeitures as they occur. 14 Segment Data Our portfolio of brands are included within two operating segments: Telehealth and WorkSimpli. We believe our current segments and brands within our segments complement one another and position us well for future growth. The Company’s Chief Executive Officer is the chief operating decision maker (“CODM”) and is responsible for reviewing segment operating results to make determinations about resources to be allocated and to assess performance. Other factors, including type of business, revenue recognition and operating results are reviewed in determining the Company’s operating segments. Fair Value of Financial Instruments The fair value of a financial instrument is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities subject to ongoing fair value measurement are categorized and disclosed into one of the three categories depending on observable or unobservable inputs employed in the measurement. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows: 1. Level 1: Inputs that are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. 2. Level 2: Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. 3. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. The fair value of the Company’s money market account is valued using Level 1 inputs. The carrying value of the Company’s financial instruments, including cash, accounts receivable, accounts payable, accrued expenses, and the face amount of notes payable and convertible long-term debt approximate fair value for all periods presented. Concentrations of Risk We are dependent on certain third-party manufacturers and pharmacies for fulfillment services, prescription medications, packaging, and finished goods. We believe that other contract manufacturers or third-party pharmacies could be quickly secured if any of our current manufacturers or pharmacies cease to perform adequately. As of September 30, 2025, one third-party pharmacy supplied 75 % of the Company’s total fulfillment services. As of December 31, 2024, three third-party pharmacies supplied 98 % of the Company’s total fulfillment services. Recent Accounting Pronouncements In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to improve its income tax disclosure requirements. Under ASU 2023-09, entities must annually: (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. The amendments in this update are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact this guidance will have on the disclosures in the consolidated financial statements. In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) to improve the disclosures about a public business entity’s expenses and provide more detailed information about the types of expenses included in certain expense captions in the consolidated financial statements. The amendments in this update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and the amendments in this update should be applied either prospectively or retrospectively. The Company is currently evaluating the impact this guidance will have on the disclosures in the consolidated financial statements. In September 2025, the FASB issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software , to simplify and modernize the accounting for internal-use software costs. The amendments remove references to prescriptive software development stages and clarify that capitalization of eligible software development costs begins when management authorizes and commits to funding the project and it is probable the project will be completed, and the software will be used as intended. The amendments in this update are effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual periods. Early adoption is permitted, and the guidance may be applied prospectively, retrospectively, or using a modified approach for in-process projects. The Company is evaluating the impact this guidance will have on the consolidated financial statements and related disclosures. All other accounting standards updates that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the unaudited condensed consolidated financial statements upon adoption. 15 NOTE 3 – REVISIONS TO PREVIOUSLY ISSUED FINANCIAL STATEMENTS The Company is revising its previously issued financial statements to correct for: (1) errors identified associated with the calculation of revenue, deferred revenue, accounts receivable and accrued expenses and (2) previously identified out-of-period adjustments. The Company has evaluated these errors in accordance with ASC 650-10-S99 and S55 (formerly Staff Accounting Bulletins (“SAB”) No. 99 and No. 108), Accounting Changes and Error Corrections. During the three months ended September 30, 2025, the Company identified errors related to the recording of net revenue as agent in certain arrangements with the Company’s third-party pharmacy providers, which resulted in the misstatement of revenue in its previously issued 2023, 2024 annual and interim financial statements and its previously issued 2025 interim financial statements. Although the Company has determined such errors to be immaterial to its previously issued financial statements, the Company has revised its previously issued financial statements to correct these errors. The cumulative impact of such errors for periods prior to 2024 of $ 106 thousand has been accounted for as an adjustment to retained earnings as of January 1, 2024. In addition, the Company previously identified various out-of-period amounts included in its previously issued financial statements that were deemed to be quantitatively and qualitatively immaterial, individually and in the aggregate, to the financial statements in the periods recorded or to the relevant prior periods. Accordingly, the Company corrected these errors in its financial statements in the periods that the errors were identified. The Company is revising its previously issued financial statements to correct for these errors in the appropriate prior periods. The immaterial errors consist of: (1) a $1.0 million understatement of an insurance receivable and corresponding liability related to a pending legal matter previously recorded on a net basis, (2) a $1.0 million, $1.0 million and $1.5 million understatement of accounts receivable and corresponding liability related to deferred costs associated with one of the Company’s net revenue arrangements with a third-party pharmacy provider as of December 31, 2024, March 31, 2025 and June 30, 2025, respectively, (3) $1.5 million in voluntary disclosure sales tax expense that was overstated for the year ended December 31, 2024 and understated by $1.5 million for the years ended December 31, 2023, 2022 and 2021 for the Company’s WorkSimpli operating segment and (4) $0.5 million in WorkSimpli distributions that understated non-controlling interest during the three months ended December 31, 2024 and overstated non-controlling interest for the first and second quarters of 2024. The Company will effect such revisions to its consolidated balance sheet as of December 31, 2024 and its consolidated statement of operations, consolidated statement of changes in stockholders’ equity (deficit) and consolidated statement of cash flows for the year ended December 31, 2024 in connection with the future filing of its 2025 Annual Report on Form 10-K, which contain this comparative period and will effect the revisions for the three months ended March 31, 2025 and the three and six months ended June 30, 2025 in connection with the future filings of its Form 10-Q which contain these comparative periods. The following tables present the effect of the revisions on the financial statements previously issued as of and for the year ended December 31, 2024, for the three months ended September 30, 2024, as of and for the nine months ended September 30, 2024, as of and for the three months ended March 31, 2025, for the three months ended June 30, 2025 and as of and for the six months ended June 30, 2025 as a result of the error corrections described above: SCHEDULE OF REVISION ON THE PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS As Previously Reported Adjustment As Revised As of and for the Year Ended December 31, 2024 As Previously Reported Adjustment As Revised Consolidated Balance Sheet: Accounts receivable $ 8,217,813 $ 2,636,271 $ 10,854,084 Other current assets $ 2,672,231 $ 1,000,000 $ 3,672,231 Total Current Assets $ 48,733,089 $ 3,636,271 $ 52,369,360 Total Assets $ 72,460,026 $ 3,636,271 $ 76,096,297 Accrued expenses $ 20,811,763 $ 2,000,000 $ 22,811,763 Deferred revenue $ 14,480,917 $ 5,145,023 $ 19,625,940 Total Current Liabilities $ 60,255,145 $ 7,145,023 $ 67,400,168 Total Liabilities $ 76,505,394 $ 7,145,023 $ 83,650,417 Accumulated deficit $ 236,253,218 $ 3,597,713 $ 239,850,931 Total LifeMD, Inc. Stockholders’ Deficit $ 5,485,501 $ 3,597,713 $ 9,083,214 Non-controlling interest $ ( 1,440,133 ) $ ( 88,961 ) $ ( 1,529,094 ) Total Stockholders’ Deficit $ 4,045,368 $ 3,508,752 $ 7,554,120 Total Liabilities, Mezzanine Equity and Stockholder’s Deficit $ 72,460,026 $ 3,636,271 $ 76,096,297 As Previously Reported Adjustment As Revised Consolidated Statement of Operations: Telehealth revenue, net $ 158,438,631 $ ( 3,614,556 ) $ 154,824,075 Total revenues, net $ 212,453,838 $ ( 3,614,556 ) $ 208,839,282 Gross profit $ 188,385,359 $ ( 3,614,556 ) $ 184,770,803 General and administrative expenses $ 72,662,021 $ ( 1,482,913 ) $ 71,179,108 Total expenses $ 204,530,040 $ ( 1,482,913 ) $ 203,047,127 Operating loss $ ( 16,144,681 ) $ ( 2,131,643 ) $ ( 18,276,324 ) Loss from operations before income taxes $ ( 18,326,498 ) $ ( 2,131,643 ) $ ( 20,458,141 ) Net loss $ ( 18,728,498 ) $ ( 2,131,643 ) $ ( 20,860,141 ) Net income attributable to noncontrolling interests $ 153,234 $ 395,641 $ 548,875 Net loss attributable to LifeMD, Inc. $ ( 18,881,732 ) $ ( 2,527,284 ) $ ( 21,409,016 ) Net loss attributable to LifeMD, Inc. common stockholders $ ( 21,987,982 ) $ ( 2,527,284 ) $ ( 24,515,266 ) Basic loss per share attributable to LifeMD, Inc. common stockholders $ ( 0.53 ) $ ( 0.07 ) $ ( 0.60 ) Diluted loss per share attributable to LifeMD, Inc. common stockholders $ ( 0.53 ) $ ( 0.07 ) $ ( 0.60 ) Consolidated Statement of Changes in Stockholders’ Equity (Deficit): Accumulated deficit $ 236,253,218 $ 3,597,713 $ 239,850,931 Non-controlling interest $ ( 1,440,133 ) $ ( 88,961 ) $ ( 1,529,094 ) Consolidated Statement of Cash Flows: Net loss $ ( 18,728,498 ) $ ( 2,131,643 ) $ ( 20,860,141 ) Accounts receivable $ ( 2,940,563 ) $ ( 1,647,760 ) $ ( 4,588,323 ) Other current assets $ ( 1,737,721 ) $ ( 1,000,000 ) $ ( 2,737,721 ) Deferred revenue $ 5,652,319 $ 4,262,316 $ 9,914,635 Accrued expenses $ 7,502,624 $ 517,087 $ 8,019,711 Net cash provided by operating activities $ 17,513,190 $ - $ 17,513,190 16 As Previously Reported Adjustment As Revised For the Three Months Ended September 30, 2024 As Previously Reported Adjustment As Revised Condensed Consolidated Statement of Operations: Telehealth revenue, net $ 40,275,546 $ ( 120,863 ) $ 40,154,683 Total revenues, net $ 53,393,157 $ ( 120,863 ) $ 53,272,294 Gross profit $ 48,379,616 $ ( 120,863 ) $ 48,258,753 General and administrative expenses $ 18,925,844 $ ( 810,701 ) $ 18,115,143 Total expenses $ 53,065,728 $ ( 810,701 ) $ 52,255,027 Operating loss $ ( 4,686,112 ) $ 689,838 $ ( 3,996,274 ) Loss from operations before income taxes $ ( 5,244,709 ) $ 689,838 $ ( 4,554,871 ) Net loss $ ( 5,477,232 ) $ 689,838 $ ( 4,787,394 ) Net loss attributable to non-controlling interests $ ( 345,767 ) $ 216,295 $ ( 129,472 ) Net loss attributable to LifeMD, Inc. $ ( 5,131,465 ) $ 473,543 $ ( 4,657,922 ) Net loss attributable to LifeMD, Inc. common stockholders $ ( 5,908,028 ) $ 473,543 $ ( 5,434,485 ) Basic loss per share attributable to LifeMD, Inc. common stockholders $ ( 0.14 ) $ 0.01 $ ( 0.13 ) Diluted loss per share attributable to LifeMD, Inc. common stockholders $ ( 0.14 ) $ 0.01 $ ( 0.13 ) As Previously Reported Adjustment As Revised As of and for the Nine Months Ended September 30, 2024 As Previously Reported Adjustment As Revised Condensed Consolidated Statement of Operations: Telehealth revenue, net $ 108,549,257 $ 1,137,797 $ 109,687,054 Total revenues, net $ 148,199,266 $ 1,137,797 $ 149,337,063 Gross profit $ 133,560,633 $ 1,137,797 $ 134,698,430 General and administrative expenses $ 52,752,961 $ ( 1,592,078 ) $ 51,160,883 Total expenses $ 150,723,556 $ ( 1,592,078 ) $ 149,131,478 Operating loss $ ( 17,162,923 ) $ 2,729,875 $ ( 14,433,048 ) Loss from operations before income taxes $ ( 18,730,666 ) $ 2,729,875 $ ( 16,000,791 ) Net loss $ ( 18,963,189 ) $ 2,729,875 $ ( 16,233,314 ) Net (loss) income attributable to noncontrolling interests $ ( 187,729 ) $ 424,766 $ 237,037 Net loss attributable to LifeMD, Inc. $ ( 18,775,460 ) $ 2,305,109 $ ( 16,470,351 ) Net loss attributable to LifeMD, Inc. common stockholders $ ( 21,105,148 ) $ 2,305,109 $ ( 18,800,039 ) Basic loss per share attributable to LifeMD, Inc. common stockholders $ ( 0.52 ) $ 0.06 $ ( 0.46 ) Diluted loss per share attributable to LifeMD, Inc. common stockholders $ ( 0.52 ) $ 0.06 $ ( 0.46 ) Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit): Accumulated deficit $ 235,370,384 $ ( 1,234,680 ) $ 234,135,704 Non-controlling interest $ ( 1,765,058 ) $ 376,962 $ ( 1,388,096 ) As Previously Reported Adjustment As Revised Condensed Consolidated Statement of Cash Flows: Net loss $ ( 18,963,189 ) $ 2,729,875 $ ( 16,233,314 ) Accounts receivable $ ( 722,251 ) $ ( 4,450,283 ) $ ( 5,222,534 ) Other current assets $ ( 1,303,495 ) $ ( 1,000,000 ) $ ( 2,303,495 ) Deferred revenue $ 7,561,943 $ 3,312,487 $ 10,874,430 Accrued expenses $ 7,704,036 $ ( 97,031 ) $ 7,607,005 Net cash provided by operating activities $ 15,944,841 $ 495,048 $ 16,439,889 Distributions to non-controlling interest $ ( 108,000 ) $ ( 495,048 ) $ ( 603,048 ) Net cash used in financing activities $ ( 2,688,722 ) $ ( 495,048 ) $ ( 3,183,770 ) 17 As Previously Reported Adjustment As Revised As of and for the Three Months Ended March 31, 2025 As Previously Reported Adjustment As Revised Condensed Consolidated Statement of Operations: Telehealth revenue, net $ 52,456,481 $ ( 1,568,582 ) $ 50,887,899 Total revenues, net $ 65,697,756 $ ( 1,568,582 ) $ 64,129,174 Gross profit $ 57,054,040 $ ( 1,568,582 ) $ 55,485,458 Operating income $ 2,542,924 $ ( 1,568,582 ) $ 974,342 Net income $ 1,916,649 $ ( 1,568,582 ) $ 348,067 Net income (loss) attributable to LifeMD, Inc. $ 1,384,804 $ ( 1,568,582 ) $ ( 183,778 ) Net income (loss) attributable to LifeMD, Inc. common stockholders $ 608,241 $ ( 1,568,582 ) $ ( 960,341 ) Basic earnings (loss) per share attributable to LifeMD, Inc. common stockholders $ 0.01 $ ( 0.03 ) $ ( 0.02 ) Diluted earnings (loss) per share attributable to LifeMD, Inc. common stockholders $ 0.01 $ ( 0.03 ) $ ( 0.02 ) Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit): Accumulated deficit $ 235,644,977 $ 5,166,295 $ 240,811,272 Non-controlling interest $ ( 1,935,978 ) $ ( 88,961 ) $ ( 2,024,939 ) Condensed Consolidated Statement of Cash Flows: Net income $ 1,916,649 $ ( 1,568,582 ) $ 348,067 Accounts receivable ( 1,974,961 ) 1,507,106 ( 467,855 ) Deferred revenue 144,985 61,475 206,460 Net cash provided by operating activities $ 3,068,387 $ - $ 3,068,387 As Previously Reported Adjustment As Revised For the Three Months Ended June 30, 2025 As Previously Reported Adjustment As Revised Condensed Consolidated Statement of Operations: Telehealth revenue, net $ 48,563,672 $ 455,210 $ 49,018,882 Total revenues, net $ 62,218,185 $ 455,210 $ 62,673,395 Gross profit $ 54,787,281 $ 455,210 $ 55,242,491 Operating loss $ ( 906,772 ) $ 455,210 $ ( 451,562 ) Net loss $ ( 1,569,799 ) $ 455,210 $ ( 1,114,589 ) Net loss attributable to LifeMD, Inc. $ ( 2,074,874 ) $ 455,210 $ ( 1,619,664 ) Net loss attributable to LifeMD, Inc. common stockholders $ ( 2,851,436 ) $ 455,210 $ ( 2,396,226 ) Basic loss per share attributable to LifeMD, Inc. common stockholders $ ( 0.06 ) $ 0.01 $ ( 0.05 ) Diluted loss per share attributable to LifeMD, Inc. common stockholders $ ( 0.06 ) $ 0.01 $ ( 0.05 ) As Previously Reported Adjustment As Revised As of and for the Six Months Ended June 30, 2025 As Previously Reported Adjustment As Revised Condensed Consolidated Statement of Operations: Telehealth revenue, net $ 101,020,153 $ ( 1,113,372 ) $ 99,906,781 Total revenues, net $ 127,915,941 $ ( 1,113,372 ) $ 126,802,569 Gross profit $ 111,841,321 $ ( 1,113,372 ) $ 110,727,949 Operating income $ 1,636,152 $ ( 1,113,372 ) $ 522,780 Operating income (loss) 1,636,152 ( 1,113,372 ) 522,780 Net income (loss) $ 346,850 $ ( 1,113,372 ) $ ( 766,522 ) Net loss attributable to LifeMD, Inc. $ ( 690,070 ) $ ( 1,113,372 ) $ ( 1,803,442 ) Net loss attributable to LifeMD, Inc. common stockholders $ ( 2,243,195 ) $ ( 1,113,372 ) $ ( 3,356,567 ) Basic loss per share attributable to LifeMD, Inc. common stockholders $ ( 0.05 ) $ ( 0.03 ) $ ( 0.08 ) Diluted loss per share attributable to LifeMD, Inc. common stockholders $ ( 0.05 ) $ ( 0.03 ) $ ( 0.08 ) Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit): Accumulated deficit $ 238,496,413 $ 4,711,085 $ 243,207,498 Non-controlling interest $ ( 2,164,934 ) $ ( 88,961 ) $ ( 2,253,895 ) Condensed Consolidated Statement of Cash Flows: Net income (loss) $ 346,850 $ ( 1,113,372 ) $ ( 766,522 ) Accounts receivable $ 887,684 $ 645,683 $ 1,533,367 Deferred revenue $ ( 2,690,893 ) $ ( 32,312 ) $ ( 2,723,205 ) Accrued expenses $ ( 5,865,264 ) $ 500,000 $ ( 5,365,264 ) Net cash provided by operating activities $ 11,707,834 $ - $ 11,707,834 These accompanying notes to the unaudited condensed consolidated financial statements reflect the impact of this revision. NOTE 4 – ACQUISITIONS On April 24, 2025, the Company closed on the OHHMD Asset Purchase Agreement (the “OHHMD APA”) with OHHMD, PLLC, a North Carolina professional limited liability company, Doug Lucas, DO, the sole member of OHHMD, and the Company’s affiliate LifeMD Southern Patient Medical Care, P.C., a Florida professional corporation (the “PC Purchaser”), whereby the Company and the PC Purchaser acquired certain intangible assets of OHHMD, a nationwide virtual care provider focused on women’s health and hormone replacement therapies. The acquisition marked the launch of the Company’s official entry into the women’s health market and establishes a scalable clinical foundation for a comprehensive virtual health program under the LifeMD brand, focused on hormone health, bone density, metabolism, and long-term wellness. 18 The Company accounted for the OHHMD APA as an acquisition of assets as it was determined that OHHMD did not have substantive processes at the acquisition date and, therefore, did not meet the definition of a business under ASC 805, Business Combinations . The purchase price consisted of 50,000 shares of the Company’s common stock, issued at closing and other nominal consideration. In April 2025, the Company issued 50,000 shares of common stock with a total fair value of $ 303 thousand in connection with the closing of the transaction and recorded an intangible asset related to the OHHMD APA of $ 303 thousand which was assigned a useful life of three years . The Company has elected to group the complementary intangible assets acquired as a single brand intangible asset. In addition, the Company agreed to make payments of up to 250,000 shares of the Company’s common stock to the sole member of OHHMD, Dr. Doug Lucas, as follows: (i) 50,000 shares of the Company’s common stock are to be issued on the first anniversary of closing, and (ii) 200,000 shares of the Company’s common stock are to be issued on the second anniversary of the closing date, subject to the achievement of certain operational milestones. The first 100,000 shares will be issued if the OHHMD brand reaches and maintains at least 2,500 active patients and quarterly revenue of $2.5 million for six full and consecutive calendar months on or prior to the 18-month anniversary of closing. The remaining 100,000 shares will be issued if the OHHMD brand reaches and maintains at least 5,000 active patients and quarterly revenue of $4.5 million for six full and consecutive calendar months on or prior to the second anniversary of closing. In connection with the OHHMD APA, LifeMD PC concurrently entered into a three-year employment agreement with Dr. Doug Lucas. Dr. Doug Lucas now serves as the Company’s Vice President, Female Health & Clinical Operations. The future unvested shares to be issued to Dr. Doug Lucas are equity classified share-based compensation to be recognized over-time and upon achievement of certain operational milestones in accordance with ASC 718, Share-Based Payment . NOTE 5 – INTANGIBLE ASSETS As of September 30, 2025 and December 31, 2024, the Company has the following amounts related to amortizable intangible assets: SCHEDULE OF INTANGIBLE ASSETS September 30, December 31, Amortizable 2025 2024 Life Amortizable Intangible Assets: ResumeBuild brand $ 4,500,000 $ 4,500,000 5 years Customer relationship asset 1,006,840 1,006,840 3 years Cleared trade name 133,339 133,339 5 years Cleared developed technology 12,920 12,920 1 year Purchased licenses 200,000 200,000 10 years Website domain names 175,397 175,397 3 years OHHMD brand 303,000 - 3 years Amortizable intangible assets 303,000 - 3 years Less: accumulated amortization ( 4,773,178 ) ( 3,997,840 ) Total intangible assets, net $ 1,558,318 $ 2,030,656 The aggregate amortization expense of the Company’s intangible assets for the three months ended September 30, 2025 and 2024 was $ 269 thousand and $ 246 thousand, respectively, and for the nine months ended September 30, 2025 and 2024 was $ 775 thousand and $ 738 thousand, respectively. NOTE 6 – ACCRUED EXPENSES As of September 30, 2025 and December 31, 2024, the Company has the following amounts related to accrued expenses: SCHEDULE OF ACCRUED EXPENSES September 30, December 31, 2025 2024 Accrued selling and marketing expenses $ 9,800,290 $ 9,149,967 Accrued compensation 3,212,847 5,469,482 Accrued legal and professional fees 2,713,962 1,825,233 Accrued deferred costs 1,800,000 1,000,000 Sales tax payable 1,467,447 2,267,447 Accrued dividends payable 776,563 776,563 Other accrued expenses 2,308,696 2,323,071 Total accrued expenses $ 22,079,805 $ 22,811,763 19 NOTE 7 – CONVERTIBLE LONG-TERM DEBT Avenue Capital Credit Facility As noted in Note 1 above, on March 21, 2023, the Company entered into the Avenue Credit Agreement and the Avenue Supplement. The Avenue Credit Agreement provides for a convertible senior secured credit facility of up to an aggregate amount of $ 40 million, comprised of the following: (1) $ 15 million in term loans funded at closing, (2) $ 5 million of additional committed term loans received on September 26, 2023 in conjunction with the Avenue First Amendment and (3) $ 20 million of additional uncommitted term loans, collectively referred to as the “Avenue Facility”. The Company issued Avenue Warrants to purchase $ 1.2 million of the Company’s common stock at an exercise price of $ 1.24 , subject to adjustments, of which $ 660 thousand have been exercised. The Avenue Warrants have a term of five years. The relative fair value of the Avenue Warrants upon closing was $ 873 thousand. In addition, Avenue converted $ 2 million of the $ 15 million in term loans funded at closing into shares of the Company’s common stock, at a price per share equal to $ 1.49 . As of September 30, 2025, there is $ 0 in term loans remaining to be converted. On November 15, 2023, Avenue converted $ 1 million of the principal amount of the outstanding term loans into shares of the Company’s common stock. This resulted in 672,042 shares of common stock issued to Avenue. Additionally on November 15, 2023, Avenue exercised 96,773 of the Avenue Warrants on a cashless basis resulting in 79,330 shares of the Company’s common stock issued. On May 29, 2025, Avenue converted $ 1 million of the principal amount of the outstanding term loans into shares of the Company’s common stock. This resulted in 672,042 shares of common stock issued to Avenue. Additionally on May 29, 2025, Avenue exercised 435,484 of the Avenue Warrants on a cashless basis resulting in 388,650 shares of the Company’s common stock issued. On August 5, 2025, the Company paid the remaining $ 14.0 million in outstanding principal payments on the Avenue Facility and the prepayment penalty as noted in the Avenue Credit Agreement. As of September 30, 2025, there are no principal payments remaining on the Avenue Facility. The Company recorded a loss on debt extinguishment of $ 1.2 million within its unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2025. Total interest expense on convertible long-term debt, inclusive of amortization of debt discounts, amounted to approximately $ 241 thousand and $ 681 thousand for the three months ended September 30, 2025 and 2024, respectively, and $ 1.5 million and $ 2.0 million for the nine months ended September 30, 2025 and 2024, respectively. NOTE 8 – STOCKHOLDERS’ EQUITY (DEFICIT) The Company has authorized the issuance of up to 100,000,000 shares of common stock, $ 0.01 par value, and 5,000,000 shares of preferred stock, $ 0.0001 par value, of which 5,000 shares are designated as Series B Convertible Preferred Stock, 1,610,000 are designated as Series A Preferred Stock and 3,385,000 shares of preferred stock remain undesignated. The Company entered into the ATM Sales Agreement whereby the Company may offer and sell, from time to time, shares of common stock. On June 7, 2024, the Company filed the 2024 Shelf. Under the 2024 Shelf at the time of effectiveness, the Company had the ability to raise up to $ 150.0 million by selling common stock, preferred stock, debt securities, warrants, and units including $ 53.3 million of its common stock under the ATM Sales Agreement. As of September 30, 2025, the Company had $ 44.6 million available under the ATM Sales Agreement. Options and Warrants During the nine months ended September 30, 2025, the Company issued an aggregate of 131,531 shares of common stock related to the cashless exercise of options. During the nine months ended September 30, 2025, the Company issued an aggregate of 390,115 shares of common stock related to the cashless exercise of warrants. During the nine months ended September 30, 2025, the Company issued an aggregate of 100,000 shares of common stock related to the exercise of warrants for total proceeds of approximately $ 465 thousand. During the nine months ended September 30, 2025, the Company issued an aggregate of 1,250 shares of common stock related to the exercise of options for total proceeds of approximately $ 6 thousand. 20 Common Stock During the nine months ended September 30, 2025, the Company issued an aggregate of 2,284,515 shares of common stock for service, including vested restricted stock. During the nine months ended September 30, 2025, the Company issued an aggregate of 50,000 shares of common stock related to the OHHMD APA. During the nine months ended September 30, 2025, the Company issued an aggregate of 762,990 shares of common stock related to the ATM Sales Agreement and net proceeds received were $ 8.7 million . On May 29, 2025, Avenue converted $ 1 million of the principal amount of the outstanding term loans into shares of the Company’s common stock. This resulted in 672,042 shares of common stock issued to Avenue. Non-controlling Interest Net income attributed to non-controlling interest amounted to approximately $ 249 thousand for the three months ended September 30, 2025 compared to net loss of $ 129 thousand for the three months ended September 30, 2024. During the three months ended September 30, 2025 and 2024, the Company paid distributions to non-controlling interest holders of approximately $ 450 thousand and $ 36 thousand, respectively. Net income attributed to the non-controlling interest amounted to $ 1.3 million and $ 237 thousand for the nine months ended September 30, 2025 and 2024, respectively. During the nine months ended September 30, 2025 and 2024, the Company paid distributions to non-controlling shareholders of $ 762 thousand and $ 603 thousand, respectively. Dividends The Company pays cumulative dividends on its Series A Preferred Stock, in the amount of $ 2.21875 per share each year, which is equivalent to 8.875 % of the $ 25.00 liquidation preference per share. Dividends on the Series A Preferred Stock are payable quarterly in arrears, on or about the 15th day of January, April, July, and October of each year. The dividends are included in the Company’s results of operations for the three and nine months ended September 30, 2025 and 2024. Dividends declared and paid on the Series A Preferred Stock during the nine months ended September 30, 2025 and 2024 are as follows: SCHEDULE OF DIVIDENDS DECLARED AND PAID ON THE SERIES A PREFERRED STOCK Declaration Date Record Date Payment Date March 25, 2025 April 4, 2025 April 15, 2025 June 23, 2025 July 3, 2025 July 15, 2025 September 23, 2025 October 3, 2025 October 15, 2025 March 26, 2024 April 5, 2024 April 15, 2024 June 25, 2024 July 5, 2024 July 15, 2024 September 24, 2024 October 4, 2024 October 15, 2024 Stock Options On January 8, 2021, the Company approved the Company’s 2020 Equity and Incentive Plan (the “2020 Plan”). Approval of the 2020 Plan was included as Proposal 1 in the Company’s definitive proxy statement for its Special Meeting of Stockholders filed with the Securities and Exchange Commission on December 7, 2020. The 2020 Plan is administered by the Compensation Committee of the Board of Directors (the “Board”) and initially provided for the issuance of up to 1,500,000 shares of Common Stock. The number of shares of Common Stock available for issuance under the 2020 Plan automatically increases by 150,000 shares of Common Stock on January 1st of each year, for a period of not more than ten years, commencing on January 1, 2021 and ending on (and including) January 1, 2030. Awards under the 2020 Plan can be granted in the form of stock options, non-qualified and incentive options, stock appreciation rights, restricted stock, and restricted stock units. On June 24, 2021, at the Annual Meeting of Stockholders, the stockholders of the Company approved the amendment and restatement to the 2020 Plan, which amended the 2020 Plan to increase the maximum number of shares of the Company’s common stock available for issuance under the 2020 Plan by 1,500,000 shares. On June 16, 2022, at the Annual Meeting of Stockholders, the stockholders of the Company approved the second amendment and restatement of the 2020 Plan, which amended the 2020 Plan to increase the maximum number of shares of the Company’s common stock available for issuance under the 2020 Plan by 1,500,000 shares. On June 14, 2024, at the Annual Meeting of Stockholders, the stockholders of the Company approved the third amendment and restatement to the 2020 Plan (the “Amended 2020 Plan”), which further amended the 2020 Plan by increasing the maximum number of shares of the Company’s common stock available for issuance under the Amended 2020 Plan by 3,000,000 shares. As of September 30, 2025, the Amended 2020 Plan provided for the issuance of up to 8,250,000 shares of Common Stock. Remaining authorization under the Amended 2020 Plan was 867,511 shares as of September 30, 2025. 21 The forms of award agreements to be used in connection with awards made under the Amended 2020 Plan to the Company’s executive officers and non-employee directors are: ● Form of Non-Qualified Option Agreement (Non-Employee Director Awards) ● Form of Non-Qualified Option Agreement (Employee Awards); and ● Form of Restricted Stock Award Agreement. Previously, the Company had granted service-based stock options and performance-based stock options separate from the Amended 2020 Plan. The following is a summary of outstanding options activity under our Amended 2020 Plan for the nine months ended September 30, 2025: SCHEDULE OF OPTION ACTIVITY Options Outstanding Number of Shares Exercise Price per Share Weighted Average Remaining Contractual Life Weighted Average Exercise Price per Share Balance, December 31, 2024 515,667 $ 1.84 – 13.74 4.81 years $ 8.28 Granted - - - - Exercised ( 31,750 ) 4.76 – 6.17 1.04 years 5.72 Cancelled/Forfeited/Expired ( 224,667 ) 4.57 – 10.93 5.74 years 9.09 Balance at September 30, 2025 259,250 $ 1.84 – 13.74 2.98 years $ 7.89 Exercisable at December 31, 2024 504,787 $ 1.84 – 13.74 4.84 years $ 8.39 Exercisable at September 30, 2025 258,972 $ 1.84 – 13.74 2.98 years $ 7.89 Total compensation expense for the Amended 2020 Plan options above was approximately $ 1 thousand and $ 109 thousand for the three months ended September 30, 2025 and 2024, respectively, with no unamortized expense remaining as of September 30, 2025. Total compensation expense under the Amended 2020 Plan options above was approximately $ 29 thousand and $ 1.2 million for the nine months ended September 30, 2025 and 2024, respectively. During the nine months ended September 30, 2025, 30,500 options were exercised on a cashless basis, which resulted in 17,613 shares issued, and 1,250 options were exercised for cash. As of September 30, 2025, aggregate intrinsic value of vested service-based options outstanding was $ 421 thousand. The following is a summary of outstanding service-based options activity (prior to the establishment of our Amended 2020 Plan above) for the nine months ended September 30, 2025: SCHEDULE OF OPTION ACTIVITY Options Outstanding Number of Shares Exercise Price per Share Weighted Average Remaining Contractual Life Weighted Average Exercise Price per Share Balance, December 31, 2024 682,333 $ 1.00 – 11.98 4.24 years $ 4.06 Granted 30,000 7.50 1.37 years 7.50 Exercised ( 197,000 ) 1.15 – 7.55 4.55 years 3.73 Cancelled/Forfeited/Expired ( 60,000 ) 2.50 – 7.50 3.62 years 5.83 Balance at September 30, 2025 455,333 $ 1.00 – 11.98 2.78 years $ 4.19 Exercisable December 31, 2024 682,333 $ 1.00 – 11.98 4.24 years $ 4.06 Exercisable at September 30, 2025 455,333 $ 1.00 – 11.98 2.78 years $ 4.19 The total fair value of the options granted during the nine months ended September 30, 2025 was $ 163 thousand, which was determined using the Black-Scholes Pricing Model with the following assumptions: dividend yield of 0 %, expected term of 5 years, volatility of 108.5 %, and risk-free rate of 4.34 %. Total compensation expense under the above service-based option plan was $ 0 and $ 25 thousand for the three months ended September 30, 2025 and 2024, respectively, with no unamortized expense remaining as of September 30, 2025. Total compensation expense under the above service-based option plan was $ 145 thousand and $ 266 thousand for the nine months ended September 30, 2025 and 2024, respectively. During the nine months ended September 30, 2025, 197,000 options were exercised on a cashless basis, which resulted in 113,918 shares issued. As of September 30, 2025, aggregate intrinsic value of vested service-based options outstanding was $ 1.3 million. 22 The following is a summary of outstanding performance-based options activity for the nine months ended September 30, 2025: SCHEDULE OF OPTION ACTIVITY Options Outstanding Number of Shares Exercise Price per Share Weighted Average Remaining Contractual Life Weighted Average Exercise Price per Share Balance at December 31, 2024 90,000 $ 1.25 – 2.50 2.30 years $ 1.69 Granted 50,000 1.25 – 1.75 1.88 years 1.50 Cancelled/Forfeited/Expired ( 60,000 ) 1.25 – 2.50 1.40 years 1.67 Balance at September 30, 2025 80,000 $ 1.25 – 1.75 1.88 years $ 1.59 Exercisable December 31, 2024 25,000 $ 1.75 – 2.50 1.40 years $ 2.05 Exercisable at September 30, 2025 65,000 $ 1.25 – 1.75 1.85 years $ 1.56 Total compensation expense under the above performance-based options plan was $ 535 thousand for the three and nine months ended September 30, 2025. No compensation expense was recognized on the performance-based options above for the three and nine months ended September 30, 2024, as the performance terms have not been met or are not probable. As of September 30, 2025, aggregate intrinsic value of vested performance options outstanding was $ 416 thousand. RSUs and RSAs (under our Amended 2020 Plan) The following is a summary of unvested RSUs and RSAs activity under our Amended 2020 Plan for the nine months ended September 30, 2025: SCHEDULE OF RESTRICTED STOCK UNIT ACTIVITY RSUs and RSAs Unvested Number of Shares Balance at December 31, 2024 3,049,944 Granted 1,493,000 Vested ( 1,890,277 ) Cancelled/Forfeited ( 45,000 ) Balance at September 30, 2025 2,607,667 The total fair value of the 1,493,000 RSUs and RSAs granted was $ 10.5 million which was determined using the fair value of the quoted market price on the date of grant. Total compensation expense under the Amended 2020 Plan RSUs and RSAs above was approximately $ 2.7 million and $ 2.1 million for the three months ended September 30, 2025 and 2024, respectively, with unamortized expense remaining of approximately $ 9.6 million as of September 30, 2025. Total compensation expense under the Amended 2020 Plan RSUs and RSAs above was $ 7.1 million and $ 6.9 million for the nine months ended September 30, 2025 and 2024, respectively. During the nine months ended September 30, 2025, 2,022,015 RSUs and RSAs were issued, which included 1,745,333 RSUs and RSAs that vested during the nine months ended September 30, 2025, and 276,682 RSUs and RSAs that vested previously. RSUs and RSAs (outside of our Amended 2020 Plan) The following is a summary of unvested RSUs and RSAs activity (outside of our Amended 2020 Plan) for the nine months ended September 30, 2025: SCHEDULE OF RESTRICTED STOCK UNIT ACTIVITY RSUs and RSAs Unvested Number of Shares Balance at December 31, 2024 300,000 Granted - Vested ( 200,000 ) Balance at September 30, 2025 100,000 23 Total compensation expense for RSUs and RSAs outside of the Amended 2020 Plan was $ 0 and $ 202 thousand for the three months ended September 30, 2025 and 2024, respectively, with no unamortized expense remaining as of September 30, 2025. Total compensation expense for RSUs and RSAs outside of the Amended 2020 Plan was $ 0 and $ 712 thousand for the nine months ended September 30, 2025 and 2024, respectively. During the nine months ended September 30, 2025, 262,500 RSUs and RSAs were issued, which included 200,000 RSUs and RSAs that vested during the nine months ended September 30, 2025 and 62,500 RSUs and RSAs that vested previously. Warrants The following is a summary of outstanding and exercisable warrants activity during the nine months ended September 30, 2025: SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE Warrants Outstanding Number of Shares Exercise Price per Share Weighted Average Remaining Contractual Life Weighted Average Exercise Price per Share Balance at December 31, 2024 1,743,730 $ 1.24 – 12.00 2.66 years $ 4.65 Exercised ( 537,984 ) 1.24 – 4.75 2.00 years 1.89 Cancelled/Forfeited/Expired - - - - Balance at September 30, 2025 1,205,746 $ 1.24 – 12.00 1.87 years $ 5.85 Exercisable December 31, 2024 1,743,730 $ 1.24 – 12.00 2.66 years $ 4.63 Exercisable September 30, 2025 1,205,746 $ 1.24 – 12.00 1.87 years $ 5.85 Total compensation expense on the above warrants for services was $ 0 for both the three and nine months ended September 30, 2025 and 2024, with no unamortized expense remaining as of September 30, 2025. During the nine months ended September 30, 2025, 437,984 warrants were exercised on a cashless basis, which resulted in 390,115 shares issued and 100,000 warrants were exercised for cash. Stock-based Compensation The total stock-based compensation expense related to common stock granted for service-based stock options, performance-based stock options, warrants, RSUs and RSAs amounted to approximately $ 3.2 million and $ 2.4 million for the three months ended September 30, 2025 and 2024, respectively, and $ 7.8 million and $ 9.1 million for the nine months ended September 30, 2025 and 2024, respectively. Such amounts are included in general and administrative expenses in the unaudited condensed consolidated statement of operations. Unamortized expense remaining related to service-based stock options, performance-based stock options, warrants, RSUs and RSAs was approximately $ 9.6 million as of September 30, 2025, which is expected to be recognized through 2028. NOTE 9 – EARNINGS (LOSS) PER SHARE Basic earnings (loss) per common share (“EPS”) is based on the weighted average number of common shares outstanding during each period presented. Shares of unissued vested restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) are included in our calculation of basic weighted average common shares outstanding. Unvested RSUs and RSAs, convertible securities, warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from diluted earnings per share when the effects would be antidilutive. The Company follows the provisions of ASC 260, Diluted Earnings per Share . In computing diluted EPS, basic EPS is adjusted for the assumed issuance of all potentially dilutive securities. The dilutive effect of call options, warrants and share-based payment awards is calculated using the “treasury stock method,” which assumes that the “proceeds” from the exercise of these instruments are used to purchase common shares at the average market price for the period. The dilutive effect of traditional convertible debt and convertible preferred stock is calculated using the “if-converted method.” Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted EPS calculation for the entire period being presented. Basic loss per share is the same as diluted net loss per share attributable to common stockholders for the three and nine months ended September 30, 2025 and 2024, because the inclusion of potential shares of common stock would have been anti-dilutive. The following table discloses the securities that were not included in the computation of diluted net earnings (loss) per share as their inclusion would have been anti-dilutive: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES 2025 2024 2025 2024 Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 RSUs and RSAs 1,619,557 2,394,915 1,357,172 2,329,055 Stock options 345,504 1,397,000 440,877 1,694,583 Warrants 622,263 1,743,730 979,360 1,960,189 Convertible long-term debt - 671,141 671,141 671,141 Total 2,587,324 6,206,786 3,448,550 6,654,968 24 NOTE 10 – LEASES The Company leases office spaces domestically under operating leases including: (1) the Company’s headquarters in New York, New York for which the lease expires in 2028, (2) a marketing and sales center in Huntington Beach, California for which the lease expires in 2027, (3) a patient care center in Greenville, South Carolina for which the lease expires in 2032, with an additional five year option to extend, for which the Company expects to utilize, and (4) a warehouse and pharmacy operations center in Lancaster, Pennsylvania for which the lease expires in 2029, with an additional five year option to extend, for which the Company expects to utilize. WorkSimpli leases two office spaces in Puerto Rico for which the leases expire in 2026. The following is a summary of the Company’s operating right-of-use assets and operating lease liabilities as of September 30, 2025: SCHEDULE OF OPERATING RIGHT OF USE OF ASSETS Right-of-use assets $ 5,578,992 Current operating lease liabilities $ 673,482 Noncurrent operating lease liabilities $ 5,851,673 The table below reconciles the undiscounted future minimum lease payments under the above noted operating leases to the total operating lease liabilities recognized on the unaudited condensed consolidated balance sheet as of September 30, 2025: SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITIES Fiscal year 2025 $ 298,556 Fiscal year 2026 1,333,216 Fiscal year 2027 1,225,154 Fiscal year 2028 925,152 Fiscal year 2029 765,837 Thereafter 5,858,722 Less: imputed interest ( 3,881,482 ) Present value of operating lease liabilities $ 6,525,155 Operating lease expenses were approximately $ 415 thousand and $ 289 thousand for the three months ended September 30, 2025 and 2024, respectively, and $ 1.2 million and $ 747 thousand for the nine months ended September 30, 2025 and 2024, respectively, and were included in other operating expenses in our unaudited condensed consolidated statement of operations. Supplemental cash flow information related to operating lease liabilities consisted of the following: SCHEDULE OF CASH FLOW INFORMATION RELATED TO OPERATING LEASE LIABILITIES September 30, 2025 2024 Cash paid for operating lease liabilities $ 655,253 $ 615,281 Supplemental balance sheet information related to operating lease liabilities consisted of the following: September 30, 2025 December 31, 2024 Weighted average remaining lease term in years 10.26 10.39 Weighted average discount rate 10.90 % 10.96 % Additionally, the Company utilizes office space in Puerto Rico on a month-to-month basis incurring rental expense of approximately $ 3 thousand per month. NOTE 11 - COMMITMENTS AND CONTINGENCIES Purchase Commitments Many of the Company’s vendors require product deposits when a purchase order is placed for goods or fulfillment services related to inventory requirements. The Company’s history of product deposits with its inventory vendors, creates an implicit purchase commitment equaling the total expected product acceptance cost in excess of the product deposit. As of September 30, 2025, the Company approximates its implicit purchase commitments to be $ 727 thousand. 25 Legal Matters In the normal course of business operations, the Company may become involved in various legal matters. As of September 30, 2025, other than as set forth below, the Company’s management does not believe that there are any potential legal matters that could have a material adverse effect on the Company’s consolidated financial position. On August 27, 2025, a purported shareholder filed a putative class action complaint in the United States District Court for the Eastern District of New York (“EDNY”) against the Company, the Company’s Chief Executive Officer, Mr. Schreiber, and the Company’s Chief Financial Officer, Mr. Benathen, (collectively, the “Defendants”), captioned Johnston v. LifeMD, Inc., et al. , Case No. 25-cv-04761, alleging: (i) violations of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Rule 10b-5 promulgated thereunder by the Defendants for making false and misleading statements; and (ii) violations of Section 20(a) of the Exchange Act by the individual officer defendants as alleged control persons. On October 24, 2025, the EDNY granted the joint motion to transfer the class action complaint from the EDNY to the United States District Court for the Southern District of New York (“SDNY”). On October 27, 2025, the plaintiffs filed motions to be appointed lead plaintiff. The Company intends to defend vigorously against the class action. In the months following filing of the class action complaint, four putative shareholder derivative complaints were filed, captioned: (i) Greenberg v. Schreiber et al ., Case No. 25-cv-5075 (EDNY), (ii) Poulos v. Schreiber et al ., Case No. 25-cv-5197 (EDNY), (iii) Shibata v. Schreiber et al. , Case No. 25-cv-5284-JMW (EDNY) and (iv) Ellis v. Schreiber, et al. 125-cv-09343 (SDNY). These complaints alleged violations of Section 14(a) of the Exchange Act, breach of fiduciary duties, aiding and abetting breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of Exchange Act Sections 10(b) and 21D by the Company’s officers and directors. The shareholder derivative complaints are based primarily on the same alleged conduct underlying the class action complaint described above, and seek damages in an unspecified amount and other relief. While the Company does not believe that any of the class action or shareholder derivative complaints will have a material adverse effect on the Company’s business, results of operations and financial condition, failure to obtain a favorable resolution of these complaints could have such a material adverse effect. On August 23, 2023, a purported putative class action complaint captioned Marden v. LifeMD, Inc., Case No. 23-cv-07469, was filed in the United States District Court for the Southern District of New York (the “Marden Complaint”) against the Company’s RexMD brand. The Marden Complaint alleges, inter alia, unauthorized disclosure of certain information of class members to third parties. On November 21, 2023, the plaintiffs amended the Marden Complaint. On March 4, 2024, the Company moved to dismiss the Marden Complaint. On July 12, 2024, the parties attended a mediation. On November 1, 2024, the plaintiffs filed a notice of voluntary dismissal of the Southern District of New York case and on November 25, 2024, the plaintiffs refiled the case via a new complaint captioned W.M.F. & Matthew Marden v. LifeMD, Inc., Case No. A-24-906800-C, in the District Court of Clark County, Nevada. On June 4, 2025, the Court approved a preliminary class action settlement. On September 30, 2025, the final approval hearing for the settlement was held, and the settlement was formally approved by the Court, certifying the class for settlement purposes and dismissing the case with prejudice. The Company recorded approximately $ 1.1 million for the estimated settlement liability, which is reflected in accrued expenses within the Company’s unaudited condensed consolidated financial statements as of September 30, 2025. On September 5, 2023, the Internal Revenue Service (the “IRS”) issued a notice of deficiency to the Company in which the IRS asserted an income tax deficiency of approximately $ 1.9 million for the Company’s tax year ending December 31, 2019. The Company timely filed a petition in the United States Tax Court disputing all of the proposed tax deficiency. The case was subsequently transferred to the Appeals Division of the IRS. Upon review of the amended return, IRS Appeals agreed to accept the amended return as filed. On April 1, 2025, the United States Tax Court issued a decision that there was no deficiency in federal income tax due for the tax year ending December 31, 2019. All of the issues in the case were resolved in the Company’s favor. NOTE 12 – RELATED PARTY TRANSACTIONS WorkSimpli Software During the nine months ended September 30, 2025 and 2024, the Company utilized CloudBoson Technologies Pvt. Ltd. (“CloudBoson”), formerly LegalSubmit Pvt. Ltd. (“LegalSubmit”), a company owned by WorkSimpli’s Chief Software Engineer, to provide software development services. The Company paid CloudBoson a total of approximately $ 1.1 million and $ 838 thousand during the three months ended September 30, 2025 and 2024, respectively, and $ 2.9 million and $ 2.7 million during the nine months ended September 30, 2025 and 2024, respectively, for these services. The Company had no outstanding payables to CloudBoson as of September 30, 2025 and owed CloudBoson $ 56 thousand as of December 31, 2024. Legal Services During the nine months ended September 30, 2024, the Company utilized King & Spalding LLP (“King & Spalding”), a large international law firm, for which an immediate family member of Robert Jindal, one of the Company’s former directors, is the Company’s relationship partner, to provide legal services. King & Spalding ceased to be a related party of the Company on December 18, 2024. The Company paid King & Spalding a total of approximately $ 140 thousand during the three months ended September 30, 2024, and $ 591 thousand during the nine months ended September 30, 2024 for these services. The Company had no outstanding payables to King & Spalding as of December 31, 2024. 26 Consulting Agreements On May 30, 2023, Will Febbo, a member of the Board, entered into a consulting services agreement with the Company, pursuant to which he provides certain investor relations and strategic business development services, in consideration for 375,000 restricted shares of the Company’s common stock, which vested in quarterly installments from August 30, 2023 through November 30, 2024. The Company issued 62,500 restricted shares of common stock, with a fair value of $ 131 thousand, related to this agreement during the nine months ended September 30, 2025. On June 14, 2023, Naveen Bhatia, a former member of the Board, entered into a consulting services agreement with the Company, pursuant to which Mr. Bhatia provided certain investor relations and strategic business development services, in consideration for 225,000 restricted shares of the Company’s common stock, which vested in six-month installments from June 14, 2023 through December 31, 2024. The Company issued 56,250 restricted shares of common stock, with a fair value of $ 168 thousand, related to this agreement during the nine months ended September 30, 2025. On January 24, 2025, Mr. Bhatia entered into another consulting services agreement with the Company, pursuant to which Mr. Bhatia provides certain strategic business development services, in consideration for 100,000 restricted shares of the Company’s common stock, of which 50,000 restricted shares vested on the execution of the agreement and 50,000 restricted shares will vest on the one-year anniversary of the agreement. The Company issued 50,000 restricted shares of common stock, with a fair value of $ 257 thousand, related to this agreement during the nine months ended September 30, 2025. Employment Agreement Effective May 1, 2024, Brian Schreiber, Logistics & Fulfillment Advisor, and a relative of the Company’s Chief Executive Officer, entered into an amended employment agreement. Mr. Schreiber’s compensation package was adjusted to reflect the increased scope of his responsibilities. The compensation adjustment, approved by the Compensation Committee of the Board, includes an annual base salary increase to $ 240 thousand. During the nine months ended September 30, 2025 and 2024, the Company paid Mr. Schreiber approximately $ 175 thousand and $ 163 thousand, respectively, in connection with his employment. On July 15, 2025, the Company entered into an amendment to the bonus agreement with Mr. Schreiber dated August 16, 2017. The amendment modifies the performance-based vesting conditions of a previously granted stock option award for 50,000 common shares, by replacing pre-tax earnings targets with Adjusted EBITDA target, which is a performance measure used in other employee bonus agreements. All other material terms of the original agreement remain unchanged. The Company recorded stock-based compensation expense related to this amendment of $ 535 thousand during the nine months ended September 30, 2025. NOTE 13 – INCOME TAXES Due to the Company’s losses and full valuation allowance, a discrete calculation was prepared for the nine month period ended September 30, 2025. The current income tax expense for the nine months ended September 30, 2025 was approximately $ 169 thousand. For the nine months ended September 30, 2024, the Company’s income tax expense was approximately $ 233 thousand. Deferred tax assets and liabilities are recognized for temporary differences between the financial reporting basis and tax basis of assets and liabilities. Management evaluates the realizability of deferred tax assets and maintains a valuation allowance as appropriate. There have been no significant changes in uncertain tax positions during the three and nine months ended September 30, 2025. On July 4, 2025, the One Big Beautiful Bill Act (the “OBBBA”) was enacted in the United States. The OBBBA includes several changes to federal tax law that generally allow for more favorable deductibility of certain business expenses beginning in 2025, including the restoration of immediate expensing of domestic R&D expenditures, reinstatement of 100% bonus depreciation, and more favorable rules for determining the limitation on business interest expense. The OBBBA also includes certain changes to the US taxation of foreign activity. The Company has evaluated the provisions of the OBBBA and determined that the enactment of the legislation is not expected to have a material impact on its income tax provision, net deferred tax assets or liabilities, or estimated annual effective tax rate for the three and nine months ended September 30, 2025. 27 NOTE 14 – SEGMENT DATA Our portfolio of brands are included within two operating segments: Telehealth and WorkSimpli. Our CODM is our Chief Executive Officer. The CODM uses segment operating income or loss to determine segment profitability in order to assess performance and allocate resources for the Company’s operating segments based on monitoring of budgeted versus actual results. Relevant segment data for the three and nine months ended September 30, 2025 and 2024 is as follows: SCHEDULE OF RELEVANT SEGMENT DATA 2025 2024 2025 2024 Three Months Ended September 30, Nine months Ended September 30, 2025 2024 2025 2024 Telehealth Revenue, net $ 47,279,933 $ 40,154,683 $ 147,186,714 $ 109,687,054 Cost of revenue 6,714,235 4,300,877 21,689,400 13,049,315 Significant Segment Expenses: Selling and marketing expenses 22,563,994 18,120,390 66,988,030 52,283,127 Payroll expenses 7,422,880 8,135,818 22,719,082 21,148,004 Merchant processing fees 1,840,614 2,000,523 5,930,182 5,036,379 Other general and administrative expenses 6,701,571 7,241,212 23,232,089 20,055,420 Other segment items (1) 5,080,013 4,101,385 13,199,909 13,672,118 Segment operating loss $ ( 3,043,374 ) $ ( 3,745,522 ) $ ( 6,571,978 ) $ ( 15,557,309 ) WorkSimpli Revenue, net $ 12,892,537 $ 13,117,611 $ 39,788,325 $ 39,650,009 Cost of revenue 693,678 712,664 1,793,133 1,589,318 Significant Segment Expenses: Selling and marketing expenses 6,910,496 8,491,282 20,805,618 24,881,353 Payroll expenses 891,089 637,206 2,286,751 3,033,994 Merchant processing fees 787,022 843,087 2,421,009 2,450,340 Other general and administrative expenses 1,426,339 1,548,028 4,243,040 4,168,593 Other segment items (1) 1,109,753 1,136,096 3,113,230 2,402,150 Segment operating income (loss) $ 1,074,160 $ ( 250,752 ) $ 5,125,544 $ 1,124,261 Consolidated Revenue, net $ 60,172,470 $ 53,272,294 $ 186,975,039 $ 149,337,063 Segment operating loss $ ( 1,969,214 ) $ ( 3,996,274 ) $ ( 1,446,434 ) $ ( 14,433,048 ) Interest expense, net ( 262,456 ) ( 558,597 ) ( 1,551,758 ) ( 1,567,743 ) Loss on debt extinguishment ( 1,155,851 ) - ( 1,155,851 ) - Net loss $ ( 3,387,521 ) $ ( 4,554,871 ) $ ( 4,154,043 ) $ ( 16,000,791 ) (1) Other segment items include stock-based compensation and depreciation and amortization for our Telehealth segment and depreciation and amortization for our WorkSimpli segment. Total Assets September 30, 2025 December 31, 2024 Telehealth $ 56,046,430 $ 65,976,661 WorkSimpli 9,936,948 10,119,636 Consolidated $ 65,983,378 $ 76,096,297 Total Assets $ 65,983,378 $ 76,096,297 Total expenditures for purchases of capitalized software, equipment, and intangible assets, which are reported on the Company’s unaudited condensed consolidated statements of cash flows totaled $ 7.6 million and $ 6.4 million for our Telehealth segment during the nine months ended September 30, 2025 and 2024, respectively, and $ 2.6 million and $ 2.4 million for our WorkSimpli segment during the nine months ended September 30, 2025 and 2024, respectively. 28 NOTE 15 – SUBSEQUENT EVENTS Stock Issued for Service In October 2025, the Company issued 68,000 shares of common stock related to vested restricted stock with a total fair value of $ 300 thousand. WorkSimpli Sale On November 4, 2025, the Company entered into and simultaneously consummated the closing of a Stock Purchase Agreement (the “Purchase Agreement”) by and among the Company, as a Seller and Seller Representative and the other seller parties thereto (collectively, the “Sellers”), WorkSimpli and Lion Buyer, LLC, a Delaware limited liability company (the “Purchaser”), for the sale by the Sellers of all of their right, title, and interest in WorkSimpli, representing 80 % of the outstanding units in WorkSimpli, to the Purchaser (the “Transaction”). The aggregate purchase price for the units is based on an enterprise value of approximately $ 65.0 million, with 46.2 %, or $ 24.0 million, paid at close as the base purchase price, subject to an adjustment holdback amount and post-closing adjustments for net working capital, cash, closing date indebtedness, and company transaction expenses, and 53.8 %, or $ 28.0 million, subject to future performance targets, for an aggregate purchase consideration to the Sellers of up to $ 52.0 million. The Company received 91.6% of the base purchase price, or $22.0 million, based on its pro rata portion of the units held by the Sellers. The Company would receive up to $25.6 million of the purchase price subject to future performance targets . The assets and liabilities and results of operations for WorkSimpli are classified in continuing operations for all periods presented in the unaudited condensed consolidated financial statements. 29